What's in Daiichi Sankyo Co., Ltd.'s pipeline?

Daiichi Sankyo Co., Ltd. has 19 drugs in our index: 15 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 3 in Phase 1.

Which companies overlap with Daiichi Sankyo Co., Ltd.'s portfolio?

Top competitors by shared drug class: , Aarxion Anda Hlding, Cosette, Direct_Rx, Generic (originally Merck).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/daiichi-sankyo.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Daiichi Sankyo Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Daiichi Sankyo Co., Ltd. (DSNKY) pipeline: 15 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

DSNKY (OTC) 15 marketed 0 filed 0 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Datroway	DERUXTECAN	marketed			Oncology	2024-01-01
Vanflyta	QUIZARTINIB	marketed		Macrophage colony-stimulating factor 1 receptor	Oncology	2023-01-01
Enhertu	trastuzumab-deruxtecan	marketed		Receptor tyrosine-protein kinase erbB-2	Oncology	2019-01-01
Savaysa	edoxaban	marketed	Factor Xa Inhibitor	Coagulation factor X	Cardiovascular	2015-01-01
TURALIO™	TURALIO™	marketed		AP2-associated protein kinase 1, Aurora kinase B, Cyclin-dependent kinase 19	Oncology
Gracevit	SITAFLOXACIN	marketed	sitafloxacin		Infectious Disease
colesevelam HCl tablets and fenofibrate tablets	colesevelam HCl tablets and fenofibrate tablets	marketed
Hydroclorothiazide	Hydroclorothiazide	marketed			Other
Low-dose colesevelam	Low-dose colesevelam	marketed
hydrochlorothiazide tablets	hydrochlorothiazide tablets	marketed	Thiazide Diuretic [EPC]
Tarlige	MIROGABALIN	marketed		Voltage-dependent calcium channel subunit alpha-2/delta-1	Metabolic
Welchol	Welchol	marketed			Metabolic

Therapeutic area mix

Oncology · 5
Metabolic · 3
Other · 3
Infectious Disease · 2
Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Aarxion Anda Hlding · 1 shared drug class
Cosette · 1 shared drug class
Direct_Rx · 1 shared drug class
Generic (originally Merck) · 1 shared drug class
Generic (originally Merck/AstraZeneca) · 1 shared drug class
Mylan Ireland Ltd · 1 shared drug class
Portola Pharms Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Daiichi Sankyo Co., Ltd.:

Cite this brief

Drug Landscape (2026). Daiichi Sankyo Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/daiichi-sankyo. Accessed 2026-06-10.